Type here to filter the list

Wednesday, Jun 29
13:05 – 13:15

LBA O-9: Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Location: Auditorium A; Level 0
Wednesday, Jun 29
13:15 – 13:25

LBA O-10: First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
Location: Auditorium A; Level 0
Abstract Presenter: Kei Muro, MD and PhD – Aichi Cancer Center Hospital
Wednesday, Jun 29
13:25 – 13:30

Discussant: LBA 0-9, LBA 0-10
Location: Auditorium A; Level 0
Discussant: Ryan Corcoran, MD PhD – MGH Cancer Center
Wednesday, Jun 29
14:10 – 14:18

SO-1: Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
Location: Auditorium A; Level 0
Abstract Presenter: Imen Ben-Ammar
Wednesday, Jun 29
14:50 – 14:58

SO-2: Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study
Location: Auditorium A; Level 0
Abstract Presenter: Paul Ross, PhD FRCP – Guy's & St Thomas' NHS Foundation Trust
Wednesday, Jun 29
17:15 – 17:27

O-1: Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study
Location: Auditorium A; Level 0
Abstract Presenter: Aiwu Ruth He
Wednesday, Jun 29
17:27 – 17:39

O-2: Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202
Location: Auditorium A; Level 0
Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
Wednesday, Jun 29
17:39 – 17:47

SO-3: Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic-cholangiocarcinoma
Location: Auditorium A; Level 0
Abstract Presenter: Margarita Rimini
Thursday, Jun 30
08:00 – 08:08

SO-4: Individual Participant Data Network Meta-Analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma
Location: Auditorium B; Level 0
Abstract Presenter: Matthieu Faron
Thursday, Jun 30
08:00 – 09:25

Session V: Presentation of Selected Non-Colorectal Cancer Abstracts
Location: Auditorium B; Level 0
Chair: Florian Lordick, MD, PhD – Leipzig University Medical Center
Chair: Juan Manuel O'Connor, MD, MSc – Instituto Alexander Fleming
Thursday, Jun 30
08:08 – 08:16

SO-5: Disease-free survival as surrogate for overall survival in neoadjuvant chemo(radio)therapy treatment of esophageal or gastro-esophageal junction carcinoma: an analysis of 4518 individual patients and 22 trials
Location: Auditorium B; Level 0
Abstract Presenter: Nicolas Cabrit
Thursday, Jun 30
08:16 – 08:24

SO-6: Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
Location: Auditorium B; Level 0
Thursday, Jun 30
08:24 – 08:34

Discussant: SO-4, SO-5, SO-6
Location: Auditorium B; Level 0
Discussant: Karin Haustermans, MD, PhD – University Hospital Gasthuisberg
Thursday, Jun 30
08:34 – 08:46

O-3: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from CheckMate 648
Location: Auditorium B; Level 0
Abstract Presenter: Ian Chau
Thursday, Jun 30
08:46 – 08:58

O-4: Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas)
Location: Auditorium B; Level 0
Abstract Presenter: Per Pfeiffer
Thursday, Jun 30
08:58 – 09:06

SO-7: Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
Location: Auditorium B; Level 0
Abstract Presenter: Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center
Thursday, Jun 30
09:06 – 09:14

SO-8: Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)
Location: Auditorium B; Level 0
Abstract Presenter: Hisato Kawakami
Thursday, Jun 30
09:14 – 09:25

Discussant: O-3, O-4, SO-7, SO-8
Location: Auditorium B; Level 0
Discussant: Kei Muro, MD and PhD – Aichi Cancer Center Hospital
Thursday, Jun 30
10:00 – 10:08

SO-9: Pathological tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trial
Location: Auditorium A; Level 0
Abstract Presenter: Avani Athauda
Thursday, Jun 30
10:08 – 10:16

SO-10: The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
Location: Auditorium A; Level 0
Abstract Presenter: Maximilian Kloft
Thursday, Jun 30
10:16 – 10:24

SO-11: Response evaluation after neoadjuvant chemotherapy for resectable gastric cancer; downsizing vs downstaging
Location: Auditorium A; Level 0
Abstract Presenter: Alina Desiree Sandø
Thursday, Jun 30
10:24 – 10:34

Discussant: SO-9, SO-10, SO-11
Location: Auditorium A; Level 0
Discussant: Magali Svrcek, MD, PhD – Sorbonne Université, AP-HP, Hôpital Saint-Antoine
Thursday, Jun 30
11:04 – 11:16

LBA-1: RATIONALE-306: Randomized, global, Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Location: Auditorium A; Level 0
Abstract Presenter: Harry Yoon
Thursday, Jun 30
15:30 – 15:42

O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study
Location: Auditorium A; Level 0
Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
Thursday, Jun 30
15:42 – 15:50

SO-12: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040
Location: Auditorium A; Level 0
Abstract Presenter: Ignacio Melero
Thursday, Jun 30
15:50 – 15:58

SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study
Location: Auditorium A; Level 0
Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
Thursday, Jun 30
15:58 – 16:06

SO-14: Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
Location: Auditorium A; Level 0
Abstract Presenter: Andrea Casadei-Gardini
Thursday, Jun 30
16:06 – 16:14

SO-15: Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma
Location: Auditorium A; Level 0
Abstract Presenter: Firas Baidoun
Thursday, Jun 30
16:14 – 16:30

Discussant: O-5, SO-12, SO-13, SO-14, SO-15
Location: Auditorium A; Level 0
Discussant: Peter R. Galle, MD, PhD – Universitätsmedizin Mainz
Friday, Jul 1
08:00 – 09:25

Session X: Presentation of Selected Colorectal Cancer Abstracts
Location: Auditorium B; Level 0
Chair: Eric Van Cutsem, MD, PhD – University Hospital Gasthuisberg/Leuven
Chair: Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center
Friday, Jul 1
08:00 – 08:08

SO-16: FIRE-4 (AIO-KRK-0114): Randomized study for a switch maintenance concept with 5-FU plus bevacizumab after induction treatment with FOLFIRI plus cetuximab versus continued treatment with FOLFIRI plus cetuximab-secondary endpoint
Location: Auditorium B; Level 0
Abstract Presenter: Volker Heinemann
Friday, Jul 1
08:08 – 08:16

SO-17: A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
Location: Auditorium B; Level 0
Abstract Presenter: Feng Wang
Friday, Jul 1
08:16 – 08:26

Discussant: SO-16, SO-17
Location: Auditorium B; Level 0
Discussant: Sharlene Gill, MD, MPH, MBA – BC Cancer - University of British Columbia
Friday, Jul 1
08:34 – 08:42

SO-18: Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: pooled analysis of PRECONNECT and TALLISUR studies
Location: Auditorium B; Level 0
Abstract Presenter: Lucjan Wyrwicz
Friday, Jul 1
08:42 – 08:50

SO-19: Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer
Location: Auditorium B; Level 0
Abstract Presenter: Hiroya Taniguchi
Friday, Jul 1
08:50 – 08:58

SO-20: Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Location: Auditorium B; Level 0
Abstract Presenter: Christophe Borg
Friday, Jul 1
08:58 – 09:09

SO-21: Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of clinical trials
Location: Auditorium B; Level 0
Abstract Presenter: Alessandra Raimondi
Friday, Jul 1
08:58 – 09:09

Discussant: SO-18, SO-19, SO-20, SO-21
Location: Auditorium B; Level 0
Discussant: Tanios Bekaii-Saab, MD – Mayo Clinic
Friday, Jul 1
09:09 – 09:17

SO-22: Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer
Location: Auditorium B; Level 0
Abstract Presenter: Benoist Chibaudel
Friday, Jul 1
09:17 – 09:25

LBA SO-23: Real-world evaluation of clinical utility of ColonAiQ® , a blood-based assay for colorectal cancer (CRC) early Detection
Location: Auditorium B; Level 0
Abstract Presenter: Yanbing Ding
Friday, Jul 1
08:00 – 08:08

SO-24: Young age as bad prognosis of colorectal cancer. An earlier screening needed?
Location: Rooms 131-132; Level 1
Abstract Presenter: German Calderillo-Ruiz
Friday, Jul 1
11:10 – 11:18

SO-25: Total neoadjuvant therapy (TNT) in early-onset (EO) vs average-onset (AO) locally advanced rectal cancer (LARC): Patient characteristics and tolerance
Location: Auditorium A; Level 0
Abstract Presenter: Madison Conces
Friday, Jul 1
16:35 – 16:55

Poster Discussion Guided Tours - Group 4: Basic Colon Cancer (PD-11, PD-13)
Location: Poster Hall; Level 0
Poster Discussant: Heinz-Josef Lenz, MD – University of Southern California
Friday, Jul 1
16:35 – 16:55

Poster Discussion Guided Tours - Group 5: Clinical Colon Cancer (PD-12, PD-14)
Location: Poster Hall; Level 0
Poster Discussant: Alberto F. Sobrero, prof – IRCCS Ospedale San Martino IST
Friday, Jul 1
17:20 – 17:28

SO-26: Identification and quantification of the microbiome in colorectal cancer metastases
Location: Auditorium A; Level 0
Abstract Presenter: Philippe Stevens
Friday, Jul 1
17:28 – 17:36

SO-27: Microbiome signature, global methylation and immune landscape in early onset colorectal cancer
Location: Auditorium A; Level 0
Abstract Presenter: Ning Jin
Friday, Jul 1
17:36 – 17:44

SO-28: Gut microbiome characterization and correlation with colonoscopy findings in oncological and non-oncological patients from a Chilean cancer center
Location: Auditorium A; Level 0
Abstract Presenter: Franz Villarroel-Espindola
Friday, Jul 1
18:05 – 18:13

SO-29: Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: Prevalence and correlation between DPYD-genotype mutations and P-uracil concentrations
Location: Auditorium A; Level 0
Abstract Presenter: Niels Paulsen
Friday, Jul 1
18:13 – 18:21

SO-30: Impact of single heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Location: Auditorium A; Level 0
Abstract Presenter: Kazuaki Harada
Saturday, Jul 2
08:15 – 08:23

SO-31: Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset
Location: Auditorium B; Level 0
Abstract Presenter: Elena Garralda, MD – Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology
Saturday, Jul 2
08:15 – 09:25

Session XIX: Presentation of Selected Abstracts on GI Cancer
Location: Auditorium B; Level 0
Chair: Josep Tabernero, MD – Vall d’Hebron University Hospital
Chair: Pierre Laurent-Puig, MD. PhD – Université de Paris
Saturday, Jul 2
08:23 – 08:31

SO-32: Entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis
Location: Auditorium B; Level 0
Abstract Presenter: Ignacio Garrido-Laguna
Saturday, Jul 2
08:31 – 08:39

SO-33: Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis
Location: Auditorium B; Level 0
Abstract Presenter: Sakti Chakrabarti
Saturday, Jul 2
08:39 – 08:49

Discussant: SO-31, SO-32, SO-33
Location: Auditorium B; Level 0
Discussant: Juan Manuel O'Connor, MD, MSc – Instituto Alexander Fleming
Saturday, Jul 2
08:49 – 08:57

LBA SO-34: Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)
Location: Auditorium B; Level 0
Abstract Presenter: Mohamed E. Salem, MD – Levine Cancer Institute
Saturday, Jul 2
08:57 – 09:05

SO-35: T-cell abundance measured by immunoSEQ predicts overall survival in colorectal cancer
Location: Auditorium B; Level 0
Abstract Presenter: Stephen Gruber
Saturday, Jul 2
09:05 – 09:13

SO-36: An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: a translational analysis of the phase II randomized AtezoTRIBE study
Location: Auditorium B; Level 0
Abstract Presenter: Carlotta Antoniotti
Saturday, Jul 2
09:30 – 09:42

O-6: Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: results of the phase III randomized TRIPLETE study by GONO
Location: Auditorium A; Level 0
Abstract Presenter: Daniele Rossini
Saturday, Jul 2
10:02 – 10:14

O-7: Evidence of therapeutic effectiveness of III line cetuximab rechallenge in appropriately selected patients: finding from long-term follow-up of CRICKET and CAVE trials
Location: Auditorium A; Level 0
Abstract Presenter: Erika Martinelli, MD, PhD – Università degli Studi della Campania Luigi Vanvitelli
Saturday, Jul 2
10:34 – 10:42

SO-37: Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: subanalysis of BEACON CRC
Location: Auditorium A; Level 0
Abstract Presenter: Kimmie Ng
Saturday, Jul 2
10:42 – 10:50

SO-38: Clinical efficacy and single cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Location: Auditorium A; Level 0
Abstract Presenter: Ryan Corcoran, MD PhD – MGH Cancer Center
Saturday, Jul 2
10:50 – 11:02

O-8: Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies
Location: Auditorium A; Level 0
Abstract Presenter: Rodrigo Toledo
Saturday, Jul 2
12:35 – 12:47

LBA-2: MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)
Location: Auditorium A; Level 0
Abstract Presenter: Jonathan Strickler, MD
Saturday, Jul 2
12:47 – 12:55

SO-39: Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
Location: Auditorium A; Level 0
Abstract Presenter: Hans Prenen
Saturday, Jul 2
15:15 – 15:23

SO-40: Measurement of circulating tumor DNA (ctDNA) in appendiceal adenocarcinoma (AA): prevalence, predictors, and correlation with clinical outcome
Location: Auditorium A; Level 0
Abstract Presenter: Mohammad Zeineddine